PT Brigit Biofarmaka Technologi Tbk (OBAT) Fair Value & Analysis
Consumer Defensive · ID · Market cap 150B IDR
Fair value as of: Jul 18, 2026
From 22 valuation models · updated 24 days ago
Share price +0.8% over the past month.
A solid business, screening 199% undervalued on our models.
What matters now
- The price is below even our cautious bear case (417.05 IDR). The market is more pessimistic than our downside scenario.
- Solid quality (59/100) at a price below fair value, the discount is the argument here, not the business quality.
- A fairly wide model range (417.05 IDR to 1,003 IDR) leaves room in how you read the outcome.
Price vs Fair Value (19 months)
White line = price, green steps = our fair value per fiscal year, dashed = 300-day average. As of Jul 18, 2026.
How to read this chart
19‑month range 193.00 IDR – 833.48 IDR · fair‑value band 417.05 IDR – 1,003 IDR · the 244.00 IDR price screens below the 729.02 IDR fair value. Green steps = our fair value per fiscal year (point-in-time, no hindsight). Dashed = 300-day average. As of Jul 18, 2026.
Analysis
PT Brigit Biofarmaka Technologi Tbk (OBAT) currently trades at 244.00 IDR, while our model-based Fair Value estimate is 729.02 IDR, implying the stock looks roughly 198.8% undervalued today. The Quality Score stands at 59/100 (solid quality), in the Consumer Defensive sector. Bull case: trading below our estimate, it may offer upside if the fundamentals hold. Bear case: a low price can be a value trap when quality is weak or the data is thin (evidence: medium), always confirm before acting.
Over the trailing twelve months, PT Brigit Biofarmaka Technologi Tbk generated revenue of 160B IDR at a net margin of 14.1%. Revenue grew 45.6% year over year. It earns a return on equity of 33.3%. Fundamentals as of Jul 18, 2026
Our scenario range runs from 417.05 IDR (bear case) to 1,003 IDR (bull case); at 244.00 IDR, the current price sits below that range. Bear and bull are the same models run on conservative and optimistic assumptions (margins, growth, valuation multiples), so a plausible valuation range, not a price target. The share trades about 57% below its 52-week high and 28% above its 52-week low, currently below its 200-day average. For context, the median of 10 Consumer Defensive peers we cover trades at -3% fair-value upside, at 199%, OBAT screens cheaper than that median.
Fair Value models
Each model estimates fair value its own way; the Fair Value above is the evidence-weighted blend. Evidence (0–100) measures how completely this model’s inputs are available: well-fed models carry more weight in the blend. The spread across models is intentional, each one stresses a different value driver; dividend models, for instance, come out structurally low when payout is small.
All 22 models by family
Widest divergence: Growth Earnings (1,702 IDR) versus Asset-Based (119.40 IDR). Highest evidence: Growth DCF (80).
Notify me when OBAT reaches fair value
Free. You confirm by email (double opt-in) and can unsubscribe anytime in one click.
Key figures & financial health
Figures from reported company fundamentals · as of Jul 18, 2026. TTM = trailing twelve months.
Quality Score breakdown
Of which business quality 59 · Market factors (momentum, volatility) 19
Non-valuation factor families (profitability, growth, cashflow, financial strength, momentum …), each academically grounded. Valuation itself sits in the Fair Value and is deliberately excluded here to avoid double-counting.
About the company
PT Brigit Biofarmaka Technologi Tbk provides manufacturing services for herbal medicine, herbal honey, skincare, cosmetics, botanical tea, and functional powdered drinks in Indonesia.
Full company description
PT Brigit Biofarmaka Technologi Tbk provides manufacturing services for herbal medicine, herbal honey, skincare, cosmetics, botanical tea, and functional powdered drinks in Indonesia. It also offers hair care products, including shampoo, conditioner, hair mask, hair tonic, hair oil, and hair serum and powder, as well as body moisturizer, body cleanser, facial cleanser, moisturizer, essence and serum, face mask, and personal care products. In addition, it provides lip gloss, cushion, foundation, eyeliner, and blush on balm. The company was founded in 2015 and is based in Sukoharjo, Indonesia.
Company description, as reported by the company or data provider.
Revenue & earnings trend
FY2023 – FY2025 · reported fiscal years
PT Brigit Biofarmaka Technologi Tbk reported revenue of 160B IDR in FY2025 versus 56.9B IDR in FY2023, a compound +67.7%/yr. Reported net income was 22.6B IDR in FY2025, compounding +37.5%/yr from FY2023.
Watch OBAT: get an alert when its fair value changes →
Peer Group
Packaged Foods · 649 stocks
How this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.
Snowflake
Five quick dimensions, each 0 to 100: VALUE (fair-value potential), FUTURE (revenue growth), PAST (return on equity), HEALTH (low debt), DIVIDEND (yield). Green = this stock, grey = typical sector peer.
Values & ESG
Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.
ESG scores are not available for this stock yet. Values and ESG data are contextual and can differ between providers.
Similar stocks
10 more Packaged Foods stocks, each showing price versus our Fair Value estimate (as of Jul 18, 2026).
| Stock | Price | Fair Value | vs Fair Value |
|---|---|---|---|
| Nestlé India Limited NESTLEIND | ₹1,427 | ₹362.37 | -75% |
| Britannia Industries Limited BRITANNIA | ₹5,413 | ₹1,870 | -65% |
| Tata Consumer Products Limited TATACONSUM | ₹1,089 | ₹327.27 | -70% |
| PT Indofood CBP Sukses Makmur Tbk ICBP | 6,650 IDR | 15,757 IDR | +137% |
| Samyang Foods Co 003230 | 1,139,000 KRW | 1,010,543 KRW | -11% |
| Patanjali Foods Limited PATANJALI | ₹413.80 | ₹157.04 | -62% |
| Vietnam Dairy Products Joint Stock Company VNM | 58,500 VND | 68,259 VND | +17% |
| PT Mayora Indah Tbk, MYOR | 1,750 IDR | 2,699 IDR | +54% |
| PT Cisarua Mountain Dairy Tbk CMRY | 4,490 IDR | 4,355 IDR | -3% |
| Nongshim Co 004370 | 348,500 KRW | 530,619 KRW | +52% |
Compare PT Brigit Biofarmaka Technologi Tbk with another stock
Price, fair value, quality and upside side by side.
Explore undervalued stocks
More undervalued Consumer Defensive stocks →
Frequently asked questions
Is PT Brigit Biofarmaka Technologi Tbk (OBAT) overvalued or undervalued?
What is the fair value of OBAT?
What is the quality score of OBAT?
What is the revenue of PT Brigit Biofarmaka Technologi Tbk (OBAT)?
What is the net profit margin of OBAT?
How we calculate Fair Value
Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data, nothing guessed.
Track PT Brigit Biofarmaka Technologi Tbk and try Pro for 14 days
One email gets you 14 days of full Pro (review alerts, the 35,000+ stock screener, the diversification check) plus the monthly Top-25 report of the most undervalued quality stocks. No card, cancel anytime.
Zero risk: nothing is ever charged. After 14 days you decide whether to stay.